Pilot appraisals of the activities of 10 specially selected 2,6-substituted-4-pyridinemethanols against acute Plasmodium falciparum infections in owl monkeys identified three derivatives that were two to three times as active as chloroquine against infections with a 4-aminoquinoline-susceptible strain and, at the same doses, were equally effective against infections with a strain fully resistant to treatment with maximally tolerated doses of chloroquine, quinine, and pyrimethamine. Two of these derivatives, 409, deemed worthy of evaluation in human volunteers, were studied in greater depth in owl monkeys infected with either the multidrug-resistant Smith strain of P. falciparum or the pyrimethamine-resistant Palo Alto strain of P. vivax. These studies showed (i) that at the same total oral dose, 3-day and 7-day treatment schedules were equally effective and slightly superior to a single-dose schedule; (ii) 98,057, a direct descendent of one of the three 4-pyridinemethanols examined in the World War II Malaria Chemotherapy Program (30) and the first of the newly synthesized derivatives to effect cure of P. berghei infections, and nine of the most promising derivatives developed subsequently (see Table 1 for identification and structures) were submitted to our laboratory for pilot appraisals of activities against infections with chloroquine-resistant and pyrimethamine-resistant strains of P. falciparum in owl monkeys. Three of the 10, 435,117,409, exhibited outstanding activity. These compounds were essentially equal to one another in activity in this human plasmodium model. They effected cure of infections with chloroquine-resistant strains at approximately one-third the dose of chloroquine required to cure infections with strains susceptible to this 4-aminoquinoline, and their effectiveness was not compromised by concomitant resistance to pyrimethamine.The